Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

NovoCure Ltd Director's Dealing 2025

Jul 1, 2025

31949_dirs_2025-07-01_2859fae7-6d1f-4a43-a0ff-a759f21047fc.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NovoCure Ltd (NVCR)
CIK: 0001645113
Period of Report: 2025-06-30

Reporting Person: Ben Arye Barak (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2025-06-30 Ordinary Shares A 769.00 $15.13 Acquired 174465.00 Direct

Footnotes

F1: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the 2025 NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2025 through June 30, 2025. This transaction is also exempt under Rule 16b-3(c).

F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2025.